arginyl-glycyl-aspartic acid peptide (Merck KGaA)

Arginyl-glycyl-aspartic acid (RGD) is a tripeptide motif that serves as the primary recognition site for several integrins, including αvβ3, αvβ5, and α5β1, which are involved in cell adhesion to the extracellular matrix. In oncology, RGD peptides are utilized for their ability to bind these integrins, which are frequently upregulated on the surface of tumor cells and angiogenic vascular endothelial cells. These peptides are developed as therapeutic antagonists to inhibit angiogenesis and tumor growth, or as targeting moieties for the delivery of cytotoxic drugs, imaging agents, and nanoparticles to the tumor site. While many RGD-based candidates, such as the cyclic peptide cilengitide, have been evaluated in clinical trials for indications like glioblastoma, the term generally refers to a broad class of molecules sharing this binding motif.

Other names

Arg-Gly-AspRGD motifarginyl-glycyl-aspartic acid